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FIGURE 1. Trial sequential analysis for a relative risk reduction of 25% of postoperative atrial fibril-
lation after an isolated coronary artery bypass grafting procedure in 7 trials that included 304 patients
reporting postoperative atrial fibrillation. Parameters are a ¼ .05 (2-sided), b ¼ .20 (power ¼ 80%),
and event frequency in the control group of 33.5%, with odds ratio as measure effects for each study.
The cumulated z curve (blue) crosses the trial sequential monitoring boundary (red curve), indicating
evidence for a beneficial effect of 25% relative risk reduction provided by the intervention. PUFA,
Polyunsaturated fatty acid.
Letters to the EditorIn conclusion, the TSA as we have
performed it confirms the results of
our previous meta-analysis on the
protective effect of preoperative n-3
PUFA supplementation for POAF pre-
vention after an isolated CABG.
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Reply to the Editor:
We greatly appreciate the insightful
comments of Cheema and Roberts1
concerning our recent article, which
evaluated a hybrid approach of staged
percutaneous coronary intervention
followed by minimally invasive valve
surgery (MIVS) in patients with
concomitant coronary and valvularof Thoracic and Cardiovascular Surgedisease.2 We concur with their com-
ments that mortality and morbidity
rates in valve surgery are highly corre-
lated with the case load of the individ-
ual surgeon. At the time our data were
gathered, each surgeon on average had
more than 20 years of experience and
was performing approximately 200
valve cases per year. We therefore do
not believe that lack of surgical
experience played a role in the
outcomes.
Cheema and Roberts1 were also
concerned that 61 of 65 hybrid pa-
tients had undergone percutaneous
coronary intervention of the left ante-
rior descending coronary artery
(LAD) before MIVS, and that only
55.5% of the stents used were drug
eluting, contending that perhaps these
patients might have been better served
with a left internal thoracic artery
graft to the LAD. In our study, 25 pa-
tients (38.5%) did have bare metal
stents placed. These patients were
more likely to have single-vessel dis-
ease, were older, and did not have a
lesion involving the proximal LAD.
Thus all the patients with a proximal
LAD lesion had drug-eluting stents
placed, not bare metal. A meta-
analysis of 9 randomized, controlled
trials that enrolled 1210 patients with
proximal LAD lesions, comparing
those who had a left internal thoracic
artery graft to the LAD with those
with a drug-eluting stent, demon-
strated no differences in survival at
30 days, 1 year, or 5 years.3 We there-
fore believe that the patients in our
study were treated appropriately.
Another concern mentioned by
Cheema and Roberts1 was that the
mitral valve repair rate in the MIVS
group was 58%, and that ‘‘perhaps
the lack of adequate exposure
inherent to a 4- to 5-cm incision
compromised the ability to attain a
satisfactory repair.’’ Although we
agree that in the hands of a high-
volume surgeon a P2 prolapse can
have a high repair rate, those were
not the type of patients we encoun-
tered. Our patient populationry c Volume 146, Number 4 993
Letters to the Editorconsisted of a group of patients who
tend to have a lower repair rate,
including 13 (54.1%) with functional
mitral regurgitation, 5 (20.8%) with a
rheumatic mitral valve, and only 6
(25%) with myxomatous degenera-
tion of the mitral valve. We would
like to clarify that the 58% mitral
valve repair rate is much higher than
the 41% mitral repair rate reported
by Bolling and colleagues4 in their re-
view of the Society of Thoracic Sur-
geons database involving 28,507
patients. We also take issue with the
comment that the lack of adequate
exposure may compromise the ability
to attain a satisfactory repair. The
ability to repair the mitral valve is
based more on the expertise of the
surgeon and the valve pathology
than on the surgical approach. Indeed,
in a report from the Society of
Thoracic Surgeons database of
28,143 patients undergoing primary
mitral valve surgery, the mitral valve
repair rates are actually higher among
patients undergoing MIVS than
among those undergoing a median
sternotomy (85% vs 67%, respec-
tively; P<.0001).5 In addition, in a
meta-analysis of 5 studies, the propor-
tion of patients with mitral postopera-
tive insufficiency, was not
significantly different between those
who had MIVS and those who had a
median sternotomy (2.4% vs 2%,
relative risk, 1.16; 95% confidence
interval, 0.38-3.57).6 In other words,
MIVS does not compromise the repair
rate, nor does it reduce the ability to
attain a satisfactory repair.994 The Journal of Thoracic and CWe agree with the final comments
of Cheema and Roberts1 concerning
the favorable effects of a concomitant
Cox maze procedure during MIVS in
patients with a history of atrial fibrilla-
tion, although this was not the focus of
our study. More important than a Cox
maze procedure, however, are the ben-
efits imparted by MIVS in reducing
the incidence of postoperative atrial
fibrillation. A meta-analysis of 8
studies containing 10,437 patients
demonstrated an incidence of atrial
fibrillation of 18% among patients un-
dergoing MIVS compared with 22%
among those undergoing median ster-
notomy (P¼ .03).6 In our own experi-
ence of 571 patients undergoing
primary valve surgery, the incidence
of postoperative atrial fibrillation
among patients undergoing MIVS
was 25%, compared with 37% among
those undergoing median sternotomy
(P ¼ .002).7
In light of the trends toward in-
creases in MIVS, we hypothesize that
there will be an increase in the number
of patients treated with a hybrid
approach. There are many unanswered
questions, however, including the ideal
patient for such an approach, the
optimal timing between procedures,
the optimal management of dual anti-
platelet therapy, and the costs. These
are answers that only a well-designed
and adequately powered randomized,
controlled trial can give us.
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